Prostate Cancer Facts: Risk, Symptoms, Screening, Survival & Treatment

Written & medically reviewed by Dr. Albana Greca, MD, MMedSc Family Physician / General Practitioner • Founder & Lead Medical Author • Last medically reviewed: September 2026

Quick Facts About Prostate Cancer

• Prostate cancer is the second most commonly diagnosed cancer in men worldwide.
• The International Agency for Research on Cancer (IARC), part of the World Health Organization (WHO), estimated about 1.47 million new prostate cancer cases worldwide in 2022.
• About 397,430 men died from prostate cancer worldwide in 2022.
• Prostate cancer accounted for the fourth-highest number of new cancer diagnoses overall when both sexes are considered.
• Incidence varies greatly between countries and regions because of differences in population age structure, ancestry, prostate-specific antigen (PSA) testing, diagnostic practices and access to health care.
• Early prostate cancer usually causes no symptoms.
• Urinary symptoms are common in older men but are often caused by benign prostatic hyperplasia (BPH) rather than cancer.
• Risk rises with age, family history, some ancestry-related factors and certain inherited pathogenic variants such as BRCA2.
• Prognosis depends strongly on stage, tumor biology and access to diagnosis and treatment; there is no single worldwide survival percentage that accurately represents every country.
• Not every prostate cancer needs immediate treatment. Active surveillance is standard for many appropriately selected low-risk cancers.

Fact 1: Prostate Cancer Is Common—but It Is Not One Disease

Prostate cancer is a malignant growth arising in the prostate gland, most often as an adenocarcinoma.

But prostate cancers vary enormously.

Some grow so slowly that they may never threaten a man’s health. Others are biologically aggressive and can spread early to lymph nodes, bone or other organs.

This is why modern treatment decisions use more than the diagnosis alone. Doctors combine:

• prostate-specific antigen (PSA);
• Gleason score / International Society of Urological Pathology (ISUP) Grade Group;
• tumor-node-metastasis (TNM) stage;
• magnetic resonance imaging (MRI) and prostate-specific membrane antigen positron emission tomography (PSMA PET) when appropriate;
• biopsy volume and pathology features;
• selected genomic information;
• life expectancy and health; and
• patient preferences.

Fact 2: Prostate Cancer Is a Major Global Cancer

The latest comprehensive worldwide estimates come from IARC/WHO GLOBOCAN 2022.

These figures are global population estimates, not an individual man’s personal risk.

They also should not be converted into a single worldwide “lifetime risk,” because lifetime risk varies by country, life expectancy, ancestry, screening intensity and competing causes of death.

Fact 3: The Global Burden Varies Greatly by Region

Prostate cancer is common worldwide, but its recorded incidence and mortality are not evenly distributed.

In GLOBOCAN 2022, the approximate share of global prostate-cancer cases was:

• Europe: 32.2%;
• Asia: 26.3%;
• Northern America: 17.4%;
• Latin America and the Caribbean: 15.4%;
• Africa: 7.0%; and
• Oceania: 1.6%.

These percentages reflect a combination of population size, population aging, genetic and ancestry-related factors, use of PSA testing, diagnostic intensity and access to medical care.

A country with more screening can record more prostate-cancer diagnoses because cancers are found that might otherwise remain undetected. Conversely, limited access to diagnosis can reduce recorded incidence while increasing the chance that cancers are found at a more advanced stage.

For that reason, international comparisons need to consider both incidence and mortality, not diagnosis counts alone.

Fact 4: Most Prostate Cancer Is Not Inherited in a Simple Mendelian Pattern

Inherited genetic factors contribute substantially to prostate-cancer susceptibility, but most cases do not follow a simple Mendelian inheritance pattern.

Prostate cancer is indeed highly heritable. The National Cancer Institute (NCI) estimates that inherited factors may account for up to about 60% of variation in prostate-cancer risk.

But “heritable” does not mean that most patients inherit one dominant prostate-cancer gene.

Risk reflects a mixture of:

• many common genetic variants, each with small effects;
• family-shared factors;
• ancestry;
• age; and
• less common pathogenic variants in genes such as BRCA2 and other DNA-repair genes.

Heritability is not the same as simple inheritance. Prostate cancer is usually genetically complex and multifactorial, not a single-gene disorder passed predictably from parent to child.

Fact 5: Family History Matters

A first-degree relative with prostate cancer increases risk.

NCI’s genetics review reports that, across studies:

• having an affected father is associated with roughly a two-fold or greater increase in risk; and
• having an affected brother is associated with an even higher relative risk.

Risk rises further when:

• several close relatives are affected;
• relatives were diagnosed before age 60–65;
• a relative died from prostate cancer at a young age; or
• the family also contains breast, ovarian, pancreatic or other hereditary-cancer patterns.

Fact 6: BRCA2 Is an Important Prostate Cancer Gene

Inherited BRCA2 pathogenic variants are associated with a higher likelihood of developing clinically significant and sometimes more aggressive prostate cancer.

Other inherited genes can also matter, including selected:

• BRCA1;
• ATM;
• CHEK2;
• HOXB13;
• mismatch-repair genes such as MSH2/MSH6; and
• other DNA-repair genes.

Somatic alterations involving genes such as ERG and ETV1 are important in prostate-cancer biology, but they are not the principal basis of inherited-risk assessment. Germline risk assessment instead focuses on established susceptibility and DNA-repair genes, family history and other guideline-supported indicators.

Genetic counseling and germline testing are particularly relevant when there is strong family history, known familial mutations, metastatic disease or other guideline-supported indications.

Fact 7: Men of African Ancestry Can Face a Higher Prostate Cancer Burden

Prostate-cancer risk and mortality differ across populations.

In the United States, Black men have substantially higher prostate-cancer incidence and mortality than White men. The American Urological Association/Society of Urologic Oncology (AUA/SUO) guideline identifies Black ancestry as an increased-risk factor when discussing earlier PSA-based screening.

Men of African descent are not one biologically uniform population, and outcomes vary greatly between countries and health systems. The higher burden observed in some populations is likely influenced by a combination of:

• inherited susceptibility and ancestry-related biology;
• differences in access to early detection;
• access to specialist care and modern treatment;
• social determinants of health;
• treatment differences; and
• other structural and environmental factors.

This is why ancestry can be relevant to risk assessment, but it should be considered together with family history, inherited mutations, age, health and local screening guidance.

Fact 8: Age Is One of the Strongest Risk Factors

Prostate cancer is strongly age-related and is uncommon in young men.

The probability of diagnosis rises substantially with increasing age, while clinically significant prostate cancer before age 40 is rare.

This age relationship is seen internationally, although the exact age distribution differs between countries because populations have different age structures, life expectancies and screening practices.

This is why screening recommendations are age- and risk-based rather than beginning in all men at a very young age.

Fact 9: Early Prostate Cancer Usually Has No Symptoms

This is one of the most important facts for patients.

Early-stage prostate cancer generally causes no symptoms.

That means relying on urinary problems as an “early warning system” can miss cancer.

When prostate cancer does cause symptoms, possible findings include:

• weak or slow urinary stream;
• urinary frequency;
• blood in the urine or semen;
• erectile problems;
• persistent bone pain in advanced disease;
• unexplained weight loss; or
• neurological symptoms when spinal metastases compress nerves.

See our prostate cancer symptoms and warning signs guide.

Fact 10: Urinary Symptoms Usually Do Not Mean Prostate Cancer

Weak stream, nocturia, urgency and incomplete emptying are extremely common in older men.

They are often caused by benign prostatic hyperplasia (BPH).

NCI specifically states that BPH:

• is not prostate cancer; and
• does not increase the risk of developing prostate cancer.

Similarly, prostatitis is not regarded as a proven prostate-cancer precursor.

Urinary symptoms still deserve evaluation because cancer, infection, stones, urethral disease and other conditions can occasionally produce similar symptoms.

Fact 11: PSA Is Not a Cancer-Specific Test

PSA stands for prostate-specific antigen, not prostate-cancer-specific antigen.

PSA can rise because of:

• prostate cancer;
• BPH;
• prostatitis/inflammation;
• urinary retention;
• recent prostate instrumentation; and
• other prostate-related factors.

There is no universal PSA value that proves cancer is present or absent.

A newly elevated PSA is often repeated before MRI, biomarkers or biopsy are considered.

See our comprehensive PSA test guide.

Fact 12: DRE Is an Adjunct, Not a Stand-Alone Screening Strategy

A digital rectal examination (DRE) can detect:

• prostate asymmetry;
• hardness;
• nodules; or
• other suspicious changes.

But DRE alone is not sensitive enough to be used as the only screening test.

Modern early-detection pathways use PSA as the primary blood test, with DRE, MRI, PSA density, risk calculators and selected biomarkers adding information when appropriate.

Fact 13: Prostate Cancer Screening Recommendations Vary by Country and Risk Profile

There is no single worldwide screening schedule that is appropriate for every man.

Recommendations differ between professional societies and national health systems because they weigh the benefits of earlier cancer detection against overdiagnosis, unnecessary biopsy and treatment-related harm.

European Association of Urology (EAU) 2026

The EAU recommends offering early PSA testing to well-informed men at elevated risk beginning at approximately:

• age 50 for men without other major risk factors;
• age 45 for men of African descent;
• age 45 for men with a family history of prostate cancer diagnosed before age 60; and
• age 40 for men carrying a BRCA2 pathogenic variant.

Follow-up intervals are then adapted to PSA level, risk and life expectancy rather than automatically repeated every year.

American Urological Association / Society of Urologic Oncology

The AUA/SUO guideline supports a baseline PSA test at approximately 45–50 years for average-risk people and recommends beginning screening at approximately 40–45 years for those at increased risk, including people with Black ancestry, germline mutations or a strong family history.

For many people between ages 50 and 69, the AUA/SUO recommends screening every 2–4 years, with intervals individualized according to PSA, health, life expectancy, risk and patient preferences.

What This Means Internationally

These are examples of major professional guidelines, not universal laws.

Men should follow the recommendations used in their own country and discuss screening earlier when they have important risk factors such as strong family history, African ancestry or an inherited cancer-susceptibility mutation.

Fact 14: Screening Has Benefits and Harms

Screening can detect clinically significant prostate cancer at an earlier stage.

But screening can also find very slow-growing cancers that would never have harmed the patient.

This is called overdiagnosis.

Overdiagnosis matters because unnecessary treatment can cause:

• erectile dysfunction;
• urinary incontinence;
• urinary irritation;
• bowel side effects; and
• psychological burden.

This is why screening should involve shared decision-making rather than being presented as a risk-free annual test.

Fact 15: An Elevated PSA Does Not Automatically Mean Biopsy

Current European Association of Urology guidance recommends that an asymptomatic man with an initial PSA between approximately 3 and 10 ng/mL have the PSA repeated before further investigation.

If concern remains, the next steps can include:

• prostate MRI;
• PSA density;
• a validated risk calculator;
• selected blood or urine biomarkers; and
• biopsy when clinically justified.

A prostate biopsy remains the method that confirms the diagnosis histologically.

Fact 16: Gleason Score Has Been Replaced by a Clearer Grade Group System

Gleason scoring is still reported, but modern pathology also uses ISUP Grade Groups 1–5.

• Grade Group 1 = Gleason 3+3=6
• Grade Group 2 = Gleason 3+4=7
• Grade Group 3 = Gleason 4+3=7
• Grade Group 4 = Gleason 8
• Grade Group 5 = Gleason 9–10

A key fact is that Gleason 6 is the lowest routinely diagnosed contemporary prostate-cancer grade, not “6 out of 10 severity.”

Read Gleason Score & Grade Group Explained.

Fact 17: Grade and Stage Are Not the Same

Grade describes how aggressive the cancer looks under the microscope.

Stage describes where the cancer is anatomically.

A high-grade cancer can still be localized, and a lower-grade cancer can occasionally present with more advanced anatomical disease.

Doctors combine both pieces of information before recommending treatment.

Fact 18: Prostate Cancer Often Spreads to Bone

When prostate cancer becomes metastatic, the skeleton is one of its most common destinations.

Bone metastases can cause:

• persistent back, hip or rib pain;
• fractures;
• high calcium or bone-related complications in some cases; and
• spinal cord compression if vertebral metastases threaten the spinal canal.

New severe back pain with leg weakness or numbness, walking difficulty, or new loss of bladder/bowel control requires emergency medical assessment.

Fact 19: Prognosis Depends Strongly on Stage and Health-Care Setting

There is no single global 5-year survival percentage that accurately describes prostate cancer everywhere.

Survival differs between countries because of:

• stage at diagnosis;
• tumor Grade Group and biology;
• access to PSA testing and imaging;
• availability of surgery, radiotherapy and systemic treatments;
• health-system capacity;
• other medical conditions; and
• differences in cancer registration and follow-up.

The broad clinical pattern is consistent: localized prostate cancer generally has a much better outlook than metastatic disease.

As one regional example, current U.S. Surveillance, Epidemiology, and End Results (SEER) data report 5-year relative survival above 99% for localized and regional prostate cancer, while distant-stage disease has a substantially lower survival rate.

Those U.S. figures should not be assumed to represent outcomes in every country.

A man’s individual prognosis depends on:

• Grade Group;
• PSA;
• extent of disease;
• genomic biology;
• overall health;
• response to therapy; and
• which modern treatments are available.

Population statistics describe groups of patients. They cannot predict exactly what will happen to one individual.

Fact 20: Not Every Prostate Cancer Needs Immediate Treatment

This is one of the most important modern changes in prostate-cancer care.

Many men with low-risk localized disease are managed with active surveillance rather than immediate surgery or radiation.

Active surveillance monitors the cancer with:

• PSA;
• clinical review;
• MRI;
• repeat biopsy when appropriate; and
• other risk assessment.

Treatment is offered if the cancer shows clinically important progression.

This avoids unnecessary treatment-related urinary or sexual side effects in men whose cancer may never become dangerous.

Fact 21: Surgery and Radiation Can Both Be Curative

For clinically significant localized disease, major curative options include:

• radical prostatectomy;
• modern external-beam radiation;
• low-dose-rate/high-dose-rate (LDR/HDR) brachytherapy; and
• combined radiation + hormone therapy for selected higher-risk cancers.

There is no single treatment that is best for every man.

The choice depends on cancer risk, urinary function, sexual function, bowel health, age, comorbidities and patient priorities.

Fact 22: High-Risk Does Not Automatically Mean Incurable

High-risk localized and some locally advanced prostate cancers can still be treated with curative intent.

Modern strategies may combine:

• surgery with additional treatment if necessary; or
• radiotherapy + long-term androgen deprivation therapy (ADT), sometimes with additional systemic therapy in selected very high-risk or node-positive disease.

See Can Prostate Cancer Be Cured?

Fact 23: Metastatic Prostate Cancer Is Usually Treated for Long-Term Control

Metastatic disease is generally not described as reliably curable with current standard treatment.

However, outcomes have improved substantially.

Modern therapy can include:

• ADT + androgen-receptor pathway inhibitors;
• selected chemotherapy-containing triplet therapy;
• poly(ADP-ribose) polymerase (PARP)-directed therapy for appropriate genomic alterations;
• PSMA-targeted radioligand therapy;
• radium-223;
• sipuleucel-T in selected men; and
• other biomarker-directed approaches.

Read our advanced prostate cancer and latest treatment guides.

Fact 24: Recurrence Does Not Automatically Mean Metastatic Disease

After surgery or radiation, the first sign that cancer may have returned is often a rising PSA.

This is called biochemical recurrence.

Some recurrences are still local and potentially curable with salvage treatment.

PSMA PET has greatly improved the ability to locate recurrent disease.

Read our prostate cancer recurrence guide.

Fact 25: Diet and Supplements Do Not Cure or Reliably Prevent Prostate Cancer

A healthy diet, exercise, weight control and smoking cessation are worthwhile for general and cardiovascular health.

But supplements should not be promoted as cancer prevention or treatment.

In particular:

• selenium failed to prevent prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT); and
• vitamin E supplementation increased prostate-cancer risk.

For evidence-based lifestyle information, see prostate cancer prevention and prostate cancer diet.

Myths vs Facts

Questions Worth Asking Your Doctor

1. What is my personal prostate-cancer risk based on age, ancestry and family history?
2. When should I begin PSA screening?
3. If my PSA is elevated, should it be repeated first?
4. Would prostate MRI help before biopsy?
5. Do I have a family history that justifies genetic counseling?
6. If cancer is diagnosed, what is my exact Grade Group?
7. What is my TNM stage?
8. Do I need PSMA PET?
9. Is active surveillance appropriate?
10. If treatment is necessary, what are the realistic benefits and quality-of-life tradeoffs?

Related Prostate Cancer Guides

• PSA Test & Screening
• Prostate Cancer Symptoms & Warning Signs
• Gleason Score & Grade Group
• Prostate Cancer Stages
• Can Prostate Cancer Be Cured?
• Prostate Cancer Prevention
• Prostate Cancer Recurrence
• Latest Prostate Cancer Treatments

Medical References

1. International Agency for Research on Cancer / World Health Organization. GLOBOCAN 2022: Prostate cancer global incidence, mortality and geographic distribution.
   https://gco.iarc.who.int/media/globocan/factsheets/cancers/27-prostate-fact-sheet.pdf

2. National Cancer Institute. Genetics of Prostate Cancer (PDQ): heritability, family history, ancestry and inherited susceptibility genes.
   https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq

3. European Association of Urology. Prostate Cancer Guidelines, 2026: risk-adapted early detection, PSA testing, MRI, biopsy pathways and genetic testing.
   https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation

4. American Urological Association / Society of Urologic Oncology. Early Detection of Prostate Cancer Guideline: baseline PSA testing, increased-risk screening and individualized screening intervals.
   https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guidelines

5. American Cancer Society. Prostate Cancer Survival Rates: regional U.S. survival data used as an illustrative example, not as a global survival estimate.
   https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/survival-rates.html

Last evidence update: September 2026.

Medical information notice: Prostate-cancer risk, screening, diagnosis and prognosis must be individualized. Global and regional population statistics cannot determine whether one man has cancer or predict his personal outcome. Screening recommendations also vary by country and health system.